zurück Home

NSCLC: praeoperative Chemotherapie

Pat. 2-3a-Survival Art RT
Chemoth. keine Chemoth.

Depierre (1)

 355 52% 41% 2xPIM prae und post-OP pT3 oder pN2 RT post-OP

Roth (2)

 60 56% 15% 3x CyEP prae- und Post-OP R2-Resektion

Rosell (3)

 60 30% 0% 3x PIM prae-OP immer post-OP

Pisters (4)

 600 48% 39% 3x Carbo-Tax nein

Gilligan (5)

 519 55% 57% 3x Platin nein

Scagliotti (6)

 270 67% 60% 3x Gemza-Cisplatin nein
Chemotherapie PIM = Cisplatin/Ifosfamide/Mitomycin CyEP = Cyclophosphamide/ Ethoposid, Cisplatin

Teil von

 Therapie des NSCLC NSCLC Tumoren des Thorax Onkologie
Quellen 1. Depierre A, et al.:
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non–small-cell lung cancer.
JCO 20(2002):247–253

2. Roth JA, et al.:
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer.
JNCI 86(1994):673–680

3. Rosell R, et al.:
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non–small-cell lung cancer.
NEJM 330(1994):153–158

4. Pisters K, et al.:
Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial.
ASCO Annual Meeting,Proceedings Part I. 25(2007,18s):7520

5. Gilligan D, et al.:
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: Results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.
Lancet 369(2007):1929–1937

6. Scagliotti GV, et al.:
A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S.T. [Abstract].
JCO 26(2008) 26:Suppl, Abstr 7507

wichtiger Hinweis! Für die Richtigkeit von Indikationen, Dosisangaben und Zielvolumina kann keine Garantie übernommen werden.
In Zweifelsfällen sind die aktuellen nationalen und internationalen Leitlinien einzusehen oder der Hersteller zu kontaktieren.
blauer Punkt

Impressum                               Zuletzt geändert am 22.04.2026 16:13